(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.
Surrozen's earnings in 2025 is -$81,704,000.On average, 1 Wall Street analyst forecast SRZN's earnings for 2025 to be -$24,232,113, with the lowest SRZN earnings forecast at -$24,232,113, and the highest SRZN earnings forecast at -$24,232,113. On average, 1 Wall Street analyst forecast SRZN's earnings for 2026 to be -$41,442,907, with the lowest SRZN earnings forecast at -$41,442,907, and the highest SRZN earnings forecast at -$41,442,907.
In 2027, SRZN is forecast to generate -$47,864,845 in earnings, with the lowest earnings forecast at -$47,864,845 and the highest earnings forecast at -$47,864,845.